These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38913573)

  • 41. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
    Akiyama N; Hozumi H; Isayama T; Okada J; Sugiura K; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respirology; 2020 Jul; 25(7):743-749. PubMed ID: 31597225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study.
    Ozaltin B; Chapman R; Arfeen MQU; Fitzpatick N; Hemingway H; Direk K; Jacob J
    Respir Res; 2024 Jun; 25(1):249. PubMed ID: 38898447
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.
    Kinder BW; Brown KK; McCormack FX; Ix JH; Kervitsky A; Schwarz MI; King TE
    Chest; 2009 Jun; 135(6):1557-1563. PubMed ID: 19255294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
    Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
    BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Davidsen JR; Shaker SB; Hundahl MP; Lomholt S; Deleuran BW; Bendstrup E; Kragstrup TW
    Scand J Immunol; 2024 Sep; 100(3):e13392. PubMed ID: 38849304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
    Peljto AL; Zhang Y; Fingerlin TE; Ma SF; Garcia JG; Richards TJ; Silveira LJ; Lindell KO; Steele MP; Loyd JE; Gibson KF; Seibold MA; Brown KK; Talbert JL; Markin C; Kossen K; Seiwert SD; Murphy E; Noth I; Schwarz MI; Kaminski N; Schwartz DA
    JAMA; 2013 Jun; 309(21):2232-9. PubMed ID: 23695349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
    Molyneaux PL; Fahy WA; Byrne AJ; Braybrooke R; Saunders P; Toshner R; Albers G; Chua F; Renzoni EA; Wells AU; Karkera Y; Oballa E; Saini G; Nicholson AG; Jenkins RG; Maher TM
    Am J Respir Crit Care Med; 2022 Jun; 205(12):1440-1448. PubMed ID: 35363592
    [No Abstract]   [Full Text] [Related]  

  • 53. Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis.
    Mochizuka Y; Suzuki Y; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Inoue Y; Yasui H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura H; Suda T
    Respirology; 2023 Aug; 28(8):775-783. PubMed ID: 37221050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
    Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 56. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
    Chien JW; Richards TJ; Gibson KF; Zhang Y; Lindell KO; Shao L; Lyman SK; Adamkewicz JI; Smith V; Kaminski N; O'Riordan T
    Eur Respir J; 2014 May; 43(5):1430-8. PubMed ID: 24177001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis.
    Pugashetti JV; Kim JS; Combs MP; Ma SF; Adegunsoye A; Linderholm AL; Strek ME; Chen CH; Dilling DF; Whelan TPM; Flaherty KR; Martinez FJ; Noth I; Oldham JM
    J Heart Lung Transplant; 2024 Jul; 43(7):1174-1182. PubMed ID: 38556070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis.
    Guiot J; Struman I; Chavez V; Henket M; Herzog M; Scoubeau K; Hardat N; Bondue B; Corhay JL; Moermans C; Louis R
    Clin Epigenetics; 2017; 9():84. PubMed ID: 28824731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.
    Fainberg HP; Moodley Y; Triguero I; Corte TJ; Sand JMB; Leeming DJ; Karsdal MA; Wells AU; Renzoni E; Mackintosh J; Tan DBA; Li R; Porte J; Braybrooke R; Saini G; Johnson SR; Wain LV; Molyneaux PL; Maher TM; Stewart ID; Jenkins RG
    Lancet Respir Med; 2024 Sep; 12(9):681-692. PubMed ID: 39025091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.